TY  - JOUR
AU  - Jimenez-Cortegana, Carlos
AU  - Sanchez-Jimenez, Flora
AU  - Perez-Perez, Antonio
AU  - Alvarez, Nerissa
AU  - Sousa, Alberto
AU  - Canton-Bulnes, Luisa
AU  - Vilariño-Garcia, Teresa
AU  - Fuentes, Sandra
AU  - Martin, Salomon
AU  - Jimenez, Marta
AU  - Leon-Justel, Antonio
AU  - de la Cruz-Merino, Luis
AU  - Garnacho-Montero, Jose
AU  - Sanchez-Margalet, Victor
PY  - 2022
DO  - 10.3389/fimmu.2021.801410
UR  - http://hdl.handle.net/10668/20577
T2  - Frontiers in immunology
AB  - Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive...
LA  - en
KW  - COVID-19
KW  - ICU
KW  - MDSCs
KW  - OX40
KW  - PD-1
KW  - SARS-CoV2
KW  - Tregs
KW  - Aged
KW  - COVID-19
KW  - Comorbidity
KW  - Critical Care
KW  - Female
KW  - Granulocytes
KW  - Humans
KW  - Immunocompromised Host
KW  - Lymphocyte Activation
KW  - Lymphocyte Count
KW  - Lymphocyte Subsets
KW  - Male
KW  - Middle Aged
KW  - Myeloid-Derived Suppressor Cells
KW  - Prospective Studies
KW  - SARS-CoV-2
KW  - Severity of Illness Index
KW  - T-Lymphocytes, Regulatory
TI  - Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19.
TY  - research article
VL  - 12
ER  -